Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Thomas Jefferson University
Sponsor:
Information provided by (Responsible Party):
Thomas Jefferson University
ClinicalTrials.gov Identifier:
NCT01972737
First received: October 24, 2013
Last updated: May 13, 2014
Last verified: May 2014

October 24, 2013
May 13, 2014
October 2013
June 2014   (final data collection date for primary outcome measure)
  • Adverse events [ Time Frame: Continuous for 6 months after vaccination. ] [ Designated as safety issue: Yes ]
    Quantify treatment-emergent and related acute and sub-acute adverse events, serious adverse events, and Grade 3 and 4 non-laboratory abnormalities for safety assessments during the 6-month period after the injection of Ad5-hGCC-PADRE.
  • Antibody responses [ Time Frame: One month following vaccination. ] [ Designated as safety issue: No ]
    Determine whether Ad5-hGCC-PADRE induces an antibody response to GCC at 1 month following vaccination with Ad5-hGCC-PADRE.
Same as current
Complete list of historical versions of study NCT01972737 on ClinicalTrials.gov Archive Site
  • T cell responses [ Time Frame: One month following vaccination. ] [ Designated as safety issue: No ]
    Determine whether Ad5-hGCC-PADRE induces a T cell response to GCC at 1 month following vaccination.
  • Persistent immunological responses [ Time Frame: Three and six months after vaccination. ] [ Designated as safety issue: No ]
    Determine whether Ad5-hGCC-PADRE induces antibody and/or T cell responses to GCC that persist at 3 months and 6 months following vaccination.
Same as current
  • Occult metastases and immune responses [ Time Frame: One, thrree, and six months following vaccination. ] [ Designated as safety issue: No ]
    Determine whether antibody and/or T cell responses to GCC following vaccination with Ad5-hGCC-PADRE are related to occult metastases in regional lymph nodes quantified by GCC qRT-PCR.
  • Race and immune responses [ Time Frame: One, three and six months following vaccination. ] [ Designated as safety issue: No ]
    Determine whether antibody and/or T cell responses to GCC following vaccination with Ad5-hGCC-PADRE are related to race.
  • Time to recurrence and disease-free survival and immune responses [ Time Frame: Annually for 5 years from the time of vaccination ] [ Designated as safety issue: No ]
    Determine whether antibody and/or T cell responses to GCC following vaccination with Ad5-hGCC-PADRE are related to time to recurrence and/or disease-free survival during the 5-year period after the injection of Ad5-hGCC-PADRE.
Same as current
 
Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer
A Phase I Study of Guanylyl Cyclase C (GCC)-Encoding Replication-Deficient Human Type 5 Recombinant Adenovirus Vaccine (Ad5-hGCC-PADRE) in Stage I and II Colon Cancer Patients

The purpose of this study is to determine the safety, tolerability and ability to stimulate hGCC-specific antibody and killer T cell immune responses of an Ad5-hGCC-PADRE vaccine in stage I and stage II Caucasian and African American colon cancer patients.

There is an unmet need for improved therapeutic paradigms in colorectal cancer, the 3rd leading cause of cancer and 2nd leading cause of cancer mortality worldwide. This need is underscored by the populations in jeopardy, including the ~100 million people in the US over 50 y that have a 1:8 risk associated with a disease-specific mortality of 50%. Mortality reflects metastatic disease: ~50% of patients initially present with regional or distant metastases, while ~20% present with occult metastases. Beyond the general population risk, there is an established stage-specific difference in outcomes in pN0 (node negative) African Americans with colorectal cancer, who exhibit ~40% excess mortality attributable to race. Reductions in mortality have been hampered by the absence of effective chemo-, radio-, and immuno- therapeutic approaches to metastatic disease. In that context, immunotherapy has been disappointing, in part, reflecting the absence of antigens that are tumor-specific, immunogenic, and universally associated with neoplasia. Moreover, the gap in survival between African Americans and Caucasians specifically reflects the inability to identify those with occult metastases who are at increased risk for developing recurrent disease.

This study advances an emerging paradigm in colorectal cancer cell detection and eradication, employing GCC as a molecular marker and immunological target. GCC is a protein whose expression is normally restricted to intestinal epithelial cells, but universally expressed by metastatic colorectal tumors. We have clinically validated the detection of occult metastases in lymph nodes by quantifying GCC mRNA (messenger RNA) by reverse transcriptase (RT)-PCR (qRT-PCR). This study revealed that occult metastases were the most powerful independent predictors of survival in pN0 patients. Further, there is a disproportionate burden of occult disease in African American, compared to Caucasian, patients. This new molecular staging platform provides a unique opportunity to identify occult metastases underlying racial disparities in disease recurrence, which could be prevented by tumor-targeted immunotherapy.

In the absence of ideal tumor antigens, immunotherapy has been directed to tissue-specific proteins. Barriers to employing self-antigens include tolerance, which limits anti-tumor immunity, and autoimmunity. The present study advances an emerging paradigm exploiting immunological compartmentalization of mucosally-restricted antigens to generate systemic antitumor immunity without autoimmunity. Asymmetry in immunological cross-talk between compartments, wherein systemic T and B cell responses rarely extend to mucosae, suggest that proteins normally expressed in mucosae, but which are expressed systemically by tumors, may serve as vaccine targets for metastases. Advantages of these cancer mucosa antigens include unique systemic immunoreactivity profiles supporting highly effective durable antitumor immunity in the context of absent immunological cross-talk between compartments restricting autoimmunity. Here, this paradigm will be advanced employing the tumor marker GCC, which induces immune responses that oppose metastatic colorectal cancer in preclinical models, without autoimmunity. This study will define the safety and immunological efficacy of adenoviral GCC vaccine in African American and Caucasian pN0 colon cancer patients with excess recurrence risk reflecting occult lymph node metastases identified by GCC qRT-PCR. This study will be the first step in translating GCC into a vaccine for the secondary prevention of metastases in African American and Caucasian colorectal cancer patients.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Colon Cancer
Biological: Ad5-hGCC-PADRE vaccine
A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
Experimental: Ad5-hGCC-PADRE Vaccine
Active vaccine
Intervention: Biological: Ad5-hGCC-PADRE vaccine

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
44
December 2018
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and Female African American or Caucasian subjects older than 18 years of age. Race will be defined by the subject.
  • Stage I or stage II (pN0) colon cancer within 3 years of surgery
  • Competent immune system, defined by the ability to make a delayed type hypersensitivity (DTH) reaction to at least one of the following: candida, mumps, tetanus or trichophyton
  • Adequate renal, liver, and bone marrow functions:

Serum creatinine ≤ 2.0 mg/dl, Hemoglobin ≥ 10.0 g/dl WBC (white blood cells) ≥ 3,000 /mm3, platelet count ≥ 100,000/mm3, total bilirubin ≤2.0 mg/ml, and albumin ≥ 3.0 g/dl

  • Lymph node specimens available for quantification of occult metastases
  • Minimum of 2 months and maximum of 36 months since surgery
  • No clinical or laboratory evidence of local or systemic recurrence at entry to the study
  • Expected survival of at least 6 months
  • Karnofsky performance status ≥ 80 (ECOG 0 or 1)
  • Willingness and ability to understand and give informed consent and follow the procedures described in the protocol

Exclusion Criteria:

  • Failure to meet any of the inclusion criteria above
  • Rectal cancer
  • Prior chemotherapy/radiotherapy/immunotherapy/experimental medications for colon cancer
  • Prior splenectomy
  • Concurrent use of systemic steroids or immunosuppressive drugs (Note: topical or inhaled aerosol steroid therapies are not contraindicated for participation in the study)
  • HIV-positive by ELISA, confirmed by Western blot
  • Active autoimmune diseases that the Investigator considers would interfere with an immunologic response (e.g., systemic lupus erythematosus, multiple sclerosis or ankylosing spondylitis)
  • Other malignancy within 5 years except curatively treated non-melanomatous skin cancer and curatively treated carcinoma in situ of the uterine cervix, or early stage (stage A or B1) prostate cancer
  • Medically-proven inflammatory bowel disease
  • Has at the time of enrollment, serious infection or other serious medical condition that implies a survival of less than six months
  • Pregnancy or lactation (serum B-human chorionic gonadotropin test must be negative in fertile women at screening visit). Subjects will be asked to use contraception during conduct of the study.
  • Past medical history of serious reaction to adenovirus vaccine
  • Mental handicap
  • Chronic diarrhea >6 times per day
Both
18 Years and older
No
Contact: Takami Sato, MD, PhD 215-955-1752 takami.sato@jefferson.edu
Contact: Scott A Waldman, MD, PhD 215-955-6086 scott.waldman@jefferson.edu
United States
 
NCT01972737
Ad5-hGCC-PADRE, SAP #4100051723
Yes
Thomas Jefferson University
Thomas Jefferson University
Not Provided
Study Director: Scott A Waldman, MD, PhD Thomas Jefferson University
Thomas Jefferson University
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP